Shareholders stimulated by Brainsway depression data

Brainsway’s transcranial magnetic stimulation system was approved in the US for depression in 2013, but the first data pitting it head-to-head against a different type of technology have only just emerged. An academic study compared Brainsway’s Deep TMS device, which uses a conformation of electromagnetic coils called H-1 with an unnamed system with coils arranged in a figure of eight. The 228-patient study, conducted in Croatia, found that patients treated with Deep TMS had numerically higher remission rates, the trial’s primary endpoint, than those treated with figure-8 TMS; both types of stimulation resulted in significantly better remission than medication alone. Whether the data will spur greater uptake of Deep TMS is not clear, though shareholders seem to think it might – Brainsway’s shares closed up 5% on the Tel Aviv exchange yesterday. The company is also trialling Deep TMS in smoking cessation and post-traumatic stress disorder, and is planning trials for opioid addiction, fatigue in multiple sclerosis and post-stroke rehabilitation. The system was cleared in the US for obsessive-compulsive disorder last year (Transcranial magnetic stimulators attract attention, August 21, 2018).

Brainsway head-to-head trial data
Therapy Brainsway's Deep TMS
(H-coil) system + medication
Figure-8 coil TMS system + medication Medication alone
No of patients 72 75 81
Remission rate (%)* 59.7 42.2 11.1
     Significance p < 0.001 vs medication p = 0.001 vs medication  
Response rate (%)** 66.7 44.0  
     Significance p = 0.04 vs Figure-8 coil    
Lowering in HAM-D17 score from baseline (%) 59.0 41.0 17.0
     Significance p < 0.001 vs medication;
p = 0.048 vs Figure-8 coil
P = 0.003 vs medication  
* Remission defined as a Hamilton Depression rating scale (HAM-D17) score of ≤ 7 after four weeks of therapy or 20 treatments.
** Response defined as ≥50% decrease in HAM-D17

Brainsway's Deep TMS system

Share This Article